Diagnostics for Mitochondrial Health
A Practitioner's Guide to Testing and Monitoring
Mitochondrial health cannot be read from a single blood test. In clinical practice it is inferred from four groups of measures: direct bioenergetic profiling, markers of oxidative damage and antioxidant reserve, inflammatory markers, and vascular function. Each group captures a different consequence of mitochondrial stress, and each has its own limits on specificity and reproducibility.
For mitoquinol, the most consistent human signal is improved endothelial function, measured as brachial artery flow-mediated dilation (FMD).¹,² Reductions in oxidised LDL, F2-isoprostanes, malondialdehyde and exercise-induced DNA damage have also been reported, but mostly in single, small trials and often under an oxidative challenge such as exercise. A practical approach is to measure at baseline, repeat after about three months under the same conditions, and judge change against the patient's own starting point rather than against a reference range alone.
Why measure mitochondrial health?
Testing gives practitioners a baseline, a way to judge whether an intervention is engaging its target, and a reason to change course when nothing moves. Without it, improvements in energy or recovery are hard to separate from placebo, seasonal change or lifestyle drift.
The case for testing is strongest where mitochondrial reactive oxygen species (ROS) are a plausible driver of the presenting problem: vascular ageing, cardiometabolic risk, high training loads, and fatigue with no clear structural cause. In these settings, excess mitochondrial ROS oxidise lipids, proteins and DNA, consume glutathione and other antioxidant reserves, activate inflammatory signalling, and reduce nitric oxide availability in the endothelium. Each of these consequences leaves a measurable trace.
Two cautions shape how results should be used. First, a biomarker change shows target engagement, not clinical benefit. Second, response depends on starting point. In healthy middle-aged men, six weeks of mitoquinol lowered skeletal muscle mitochondrial hydrogen peroxide but did not change urinary F2-isoprostanes, plasma TBARS or mitochondrial respiration.³ In a crossover trial, a single 80 mg dose improved FMD in non-exercising adults but not in fitter, regularly exercising adults, and the gain was largest in those with low baseline FMD.⁴ Patients with little oxidative burden may show little measurable change.
Building a testing strategy
The table below groups the options by what they measure and when each is most useful.
| Clinical question | Measures | Example tests | Best suited to |
|---|---|---|---|
| How are the mitochondria performing? | Respiration, glycolytic reserve, ROS output, network structure | mescreen™ Complete panel | Fatigue, performance and longevity work where a direct functional readout is wanted |
| Is oxidative damage elevated? | Lipid peroxidation, DNA oxidation, glutathione status | Precision Point Advanced Oxidative Stress; Genova Oxidative Stress 2.0; Quest oxidised LDL | Most patients; the core monitoring panel for a mitochondria-targeted antioxidant |
| Is inflammation contributing? | IL-6, hs-CRP | Quest, LabCorp, InsideTracker panels | Cardiometabolic risk, ageing, chronic low-grade inflammation |
| Is cardiovascular health affected? | Blood pressure, lipid oxidation, cardiometabolic load, functional capacity | Office and home blood pressure; oxidised LDL with lipid panel; HbA1c; 6-minute walk or sit-to-stand test | Vascular ageing, hypertension, cardiometabolic risk |
| What is the wider nutritional and metabolic picture? | Antioxidant nutrients, organic acids, cofactors, toxin and methylation markers | Genova NutrEval® | Complex presentations; identifying cofactor gaps before or alongside treatment |
Pre-analytical consistency
Small procedural differences can produce changes as large as a treatment effect. Keep the following constant between baseline and follow-up:
Same laboratory and test: assays for lipid peroxides and ROS differ between laboratories and are not interchangeable.
Time of day and fasting state: particularly for oxidised LDL, lipids, glucose and blood pressure.
Recent exercise: hard exercise acutely raises F2-isoprostanes and DNA damage markers, so avoid strenuous sessions for 24–48 hours before sampling unless exercise is the planned challenge.⁶,⁷
Urine collection: follow the kit's fluid guidance, avoid collection during menstruation, and note that abnormal kidney function or diuretics can affect results.⁸
Concurrent supplements: record other antioxidants, CoQ10, NAC or high-dose vitamin C and E, which can shift the same markers.
mescreen™ Complete panel
The mescreen™ panel, developed by Verséa, brings a version of this profiling to a blood sample. The Complete panel reports four groups of outputs:
Mitochondrial stress and ATP production: respiration, efficiency and mitochondrial potential, with an index score compared against people of similar demographics.
Bio-energy profile: glycolytic and aerobic energy production at basal and stressed states, and a measure of cellular quiescence.
Free radical production: ROS output under stressed and unstressed conditions.
Network imaging: the structure and connectivity of the mitochondrial network.
The panel is the closest a practitioner can get to a functional mitochondrial readout without a biopsy. Its limitations should be explained to patients. It is a proprietary assay with limited independent peer-reviewed validation, it reflects blood-derived measures rather than muscle, heart or brain tissue, and commentators have noted it does not match biopsy-based respirometry.⁹ Repeat tests should use the same collection conditions.
No published mitoquinol trial has yet used mescreen™ as an outcome. The print guide's figure of a 48% reduction in ROS comes from a serum ROS assay in trained cyclists, not from mescreen™.¹⁰ Muscle respirometry data are mixed: six weeks of mitoquinol lowered mitochondrial hydrogen peroxide in middle-aged men without changing respiration.³ These are reasonable hypotheses to test with mescreen™, but published effect sizes should not be presented as mescreen™ results.
Specialist markers
Serum GDF-15 and FGF-21 rise in primary mitochondrial disease, and a meta-analysis found GDF-15 the more accurate of the two for diagnosis.¹¹ Both also rise with ageing, metabolic disease and other stressors, so they are referral and specialist tools rather than markers for monitoring supplementation. Suspected primary mitochondrial disease needs specialist assessment and genetic testing.
Oxidative stress and antioxidant capacity
Oxidative stress develops when ROS production, much of it from the mitochondrial electron transport chain, outpaces the cell's antioxidant capacity. It is the most direct downstream readout for a mitochondria-targeted antioxidant and the core of most monitoring panels. A useful panel pairs a damage marker with a reserve marker, so that a change in one can be read against the other.
Recommended tests
| Test | Sample | What it measures | Notes |
|---|---|---|---|
| Precision Point Diagnostics, Advanced Oxidative Stress12 | Whole blood and urine | Total and reduced glutathione (reserve); F2-isoprostanes (lipid oxidation); 8-OHdG (DNA oxidation) | The most complete single panel; pairs reserve with two damage markers |
| Genova Diagnostics, Oxidative Stress 2.08 | First-morning urine | Lipid peroxides (TBARS, which includes malondialdehyde); 8-OHdG | Simple, non-invasive; TBARS is less specific than F2-isoprostanes |
| Quest Diagnostics, oxidised LDL | Serum or plasma | Oxidatively modified LDL particles | Links oxidative stress to vascular risk; the oxidative marker most often lowered by mitoquinol in trials |
Interpreting results in practice
Look for agreement across domains: a fall in oxidised LDL alongside better FMD or blood pressure is more convincing than a single isolated marker moving.
Expect the most change where the burden is highest: raised oxidative markers, impaired vascular function, high training load or established cardiometabolic disease predict a larger response.¹,⁴
Keep symptoms and function in view: fatigue scores, exercise tolerance and quality of life are what patients notice, and no biomarker here is validated as a substitute for them.
What the mitoquinol evidence shows
Oxidised LDL: in older adults with impaired endothelial function, six weeks of 20 mg/day lowered plasma oxidised LDL compared with placebo.¹ Plasma from treated participants later improved nitric oxide production and lowered mitochondrial ROS in cultured endothelial cells, an effect that blocking the oxidised LDL receptor LOX-1 prevented.¹³
F2-isoprostanes: in trained middle-aged male cyclists, four weeks of supplementation was associated with lower plasma F2-isoprostanes after exercise.⁷
DNA damage: three weeks of 20 mg/day reduced exercise-induced nuclear and mitochondrial DNA damage in lymphocytes and skeletal muscle. A single dose did not, likely because of insufficient initial bioavailability.⁶
ROS and antioxidant enzymes: in cyclists undergoing four weeks of vigorous training, mitoquinol lowered serum ROS and increased glutathione peroxidase.¹⁰ In hypertensive men, six weeks of 20 mg/day was associated with lower malondialdehyde and higher total antioxidant capacity.¹⁴ Skeletal muscle catalase expression rose after six weeks in healthy middle-aged men.³
Null results: the same middle-aged men showed no change in urinary F2-isoprostanes or plasma TBARS.³ In peripheral artery disease, a single 80 mg dose improved superoxide dismutase but did not change malondialdehyde or total antioxidant capacity.¹⁵
Effects are clearest when oxidative burden is raised, by exercise, ageing with endothelial dysfunction, or hypertension, and smaller or absent in healthy people at rest. A patient with normal baseline oxidative markers is unlikely to show a meaningful drop, and that result is not evidence that the intervention has failed.
Inflammation
Mitochondria act as signalling hubs for innate immunity. When damaged, they release ROS, oxidised mitochondrial DNA and other molecules that the immune system reads as danger signals, activating the NLRP3 inflammasome and downstream cytokines such as IL-1β and IL-6.¹⁶ Persistent low-grade inflammation in turn impairs mitochondrial function, so the two tend to reinforce each other.
IL-6 and high-sensitivity C-reactive protein (hs-CRP) are widely available through Quest Diagnostics, LabCorp and consumer platforms such as InsideTracker. Some cardiovascular panels package them with lipid profiles. They are inexpensive, reproducible and useful for overall risk, but they are not specific to mitochondria and respond to infection, injury, sleep loss and body composition change.
The mitoquinol evidence on inflammation is mixed. In men with hypertension, six weeks of 20 mg/day was associated with lower IL-6, with effects reported for mitoquinol, exercise training and their combination.¹⁴ In healthy older adults, circulating inflammatory markers did not change despite clear improvements in endothelial function.¹ Treat inflammatory markers as context for interpreting other results, and expect change mainly where inflammation is raised at baseline.
Cardiovascular health
Vascular function is where mitoquinol's human evidence is strongest, but the main trial outcome, flow-mediated dilation (FMD), is a research technique. It needs specialised ultrasound, a trained operator and a strict protocol, so it is not available in most clinics. Practitioners can track the same biology with measures that are routine in practice.
Measures available in clinic
| Measure | How | What it reflects | Notes |
|---|---|---|---|
| Blood pressure | Validated automated cuff in clinic, plus a week of morning and evening home readings | Vascular tone and arterial load; lower FMD is independently associated with higher systolic pressure18 | Home averages are more reliable than single office readings; a context and safety measure more than a response marker |
| Oxidised LDL with a lipid panel | Blood test (Quest and other laboratories) | Lipid oxidation that impairs the endothelium | The blood marker most often lowered by mitoquinol; pairs well with blood pressure |
| Glucose, HbA1c and fasting insulin | Blood test | Cardiometabolic load; diabetes is independently associated with lower FMD18 | Context for interpreting oxidative and inflammatory markers |
| Functional capacity | 6-minute walk test or 30-second sit-to-stand | Oxygen delivery and use during everyday effort | No equipment needed; in peripheral artery disease, mitoquinol increased maximal walking time and distance15 |
Blood pressure has not changed consistently in mitoquinol trials. A single 80 mg dose did not lower it in peripheral artery disease, and four weeks of 20 mg/day left central aortic pressures unchanged in chronic kidney disease.¹⁵,¹⁷ A stable reading does not mean the intervention has not engaged its target.
What the trials measured
FMD has improved with mitoquinol in several independent trials:
Healthy older adults with impaired endothelial function (FMD <6%): 20 mg/day for six weeks raised FMD 42% versus placebo, and lowered aortic stiffness in those with elevated baseline stiffness.¹
Peripheral artery disease: a single 80 mg dose raised brachial FMD by about 2.6 and popliteal FMD by about 3.3 percentage points.¹⁵
Chronic kidney disease: 20 mg/day for four weeks raised FMD from 2.4% to 4.0%, while it fell from 4.2% to 2.5% with placebo.¹⁷
Middle-aged and older adults: a single 80 mg dose raised FMD by 2.1 percentage points in non-exercisers but not in regular exercisers. Benefit was greatest in those with baseline FMD below 6%.⁴
A 2022 meta-analysis pooling three trials found a significant improvement in FMD with mitochondria-targeted antioxidants, but rated the certainty of evidence very low because of small samples and differing populations.² A 112-participant, three-month trial of 20 mg/day in adults aged 60 and over reached its scheduled primary completion in December 2025; its published results should clarify the effect size.⁵ In hypertensive men, mitoquinol with or without exercise training improved left ventricular mass and chamber dimensions on echocardiography.¹⁴
Comprehensive nutritional and metabolic panels
Genova Diagnostics' NutrEval® combines blood and urine to report more than 125 biomarkers.¹⁹ For mitochondrial work, its value is breadth. It shows whether the cofactors and antioxidant reserves that mitochondria depend on are adequate before any targeted intervention is judged.
The panel covers five areas relevant here:
Oxidative stress: glutathione and CoQ10 as antioxidant reserve, with lipid peroxides and 8-OHdG as damage markers.
Mitochondrial and energy metabolism: organic acids from fatty acid, carbohydrate and citric acid cycle metabolism, which can point to a block in a specific pathway or a missing cofactor.
Malabsorption and dysbiosis markers: relevant because nutrient absorption limits mitochondrial supply.
Toxin exposure: markers of detoxification load.
Methylation: markers of B-vitamin and one-carbon metabolism.
NutrEval is most useful in complex presentations and at baseline. A clear deficiency in B vitamins, magnesium, CoQ10 or carnitine should be corrected first, because a mitochondria-targeted antioxidant cannot make up for missing substrates. It is less suited to repeated short-interval monitoring because of its cost and the number of markers that can vary by chance.
Human biomarker evidence for mitoquinol
The table lists measurable outcomes from human trials of mitoquinol, grouped by domain and including null results. Effects are versus placebo unless stated. Most trials are small, and several measured outcomes after an exercise challenge, so effect sizes should not be expected at rest.
| Domain | Biomarker | Population (n) | Dose and duration | Reported effect | Ref |
|---|---|---|---|---|---|
| Vascular | Brachial FMD | Healthy older adults with FMD <6% (20) | 20 mg/day, 6 weeks | 42% higher | 1 |
| Vascular | Brachial FMD | Chronic kidney disease (18) | 20 mg/day, 4 weeks | 2.4% to 4.0%; placebo fell 4.2% to 2.5% | 17 |
| Vascular | Brachial and popliteal FMD | Peripheral artery disease (11) | 80 mg, single dose | About +2.6 and +3.3 percentage points | 15 |
| Vascular | Brachial FMD | Non-exercising middle-aged and older adults (12) | 80 mg, single dose | +2.1 percentage points; no effect in exercisers | 4 |
| Vascular | Aortic stiffness (carotid-femoral PWV) | Older adults with PWV >7.6 m/s (11) | 20 mg/day, 6 weeks | Lower | 1 |
| Oxidative stress | Oxidised LDL | Healthy older adults (20) | 20 mg/day, 6 weeks | About 13% lower | 1 |
| Oxidative stress | Serum ROS | Trained cyclists (32) | 20 mg/day, 4 weeks | Up to 48% lower | 10 |
| Oxidative stress | Plasma F2-isoprostanes | Trained middle-aged male cyclists | 20 mg/day, 4 weeks | About 18% lower after exercise | 7 |
| Oxidative stress | Nuclear DNA damage (lymphocytes) | Healthy young men (24) | 20 mg/day, 3 weeks | About 21% lower after exercise | 6 |
| Oxidative stress | Mitochondrial DNA damage | Healthy young men (24) | 20 mg/day, 3 weeks | About 15% lower after exercise | 6 |
| Oxidative stress | Malondialdehyde | Men with hypertension (52) | 20 mg/day, 6 weeks | About 12% lower than baseline | 14 |
| Oxidative stress | Urinary F2-isoprostanes; plasma TBARS | Healthy middle-aged men (20) | 20 mg/day, 6 weeks | No change | 3 |
| Antioxidant capacity | Total antioxidant capacity | Men with hypertension (52) | 20 mg/day, 6 weeks | About 10% higher than baseline | 14 |
| Antioxidant capacity | Glutathione peroxidase | Trained cyclists (32) | 20 mg/day, 4 weeks | About 12% higher | 10 |
| Antioxidant capacity | Muscle catalase protein | Healthy middle-aged men (20) | 20 mg/day, 6 weeks | Higher | 3 |
| Antioxidant capacity | Malondialdehyde; total antioxidant capacity | Peripheral artery disease (11) | 80 mg, single dose | No change | 15 |
| Inflammation | IL-6 | Men with hypertension (52) | 20 mg/day, 6 weeks | About 27% lower than baseline | 14 |
| Inflammation | Circulating inflammatory markers | Healthy older adults (20) | 20 mg/day, 6 weeks | No change | 1 |
Key takeaways
Mitochondrial health is assessed indirectly, through bioenergetics, oxidative stress, inflammation and vascular function. Choose the domains that match the clinical question.
Pair a damage marker with a reserve marker, and keep laboratory, timing, fasting and recent exercise constant between tests.
FMD has the most consistent trial evidence for mitoquinol but is a research measure. In clinic, track oxidised LDL, blood pressure and functional capacity instead.
Responses are largest when oxidative or vascular burden is high, so a flat result in a healthy patient is expected rather than a failure.
Measure at baseline and again at about three months, and interpret biomarkers alongside symptoms and function.
References
Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71(6):1056-1063. doi:10.1161/HYPERTENSIONAHA.117.10787
Mason SA, Wadley GD, Keske MA, et al. Effect of mitochondrial-targeted antioxidants on glycaemic control, cardiovascular health, and oxidative stress in humans: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2022;24(6):1047-1060. doi:10.1111/dom.14669
Pham T, MacRae CL, Broome SC, et al. MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men. Eur J Appl Physiol. 2020;120(7):1657-1669. doi:10.1007/s00421-020-04396-4
Carlini NA, Harber MP, Fleenor BS. Acute effects of MitoQ on vascular endothelial function are influenced by cardiorespiratory fitness and baseline FMD in middle-aged and older adults. J Physiol. 2024;602(9):1923-1937. doi:10.1113/JP285636
Murray KO, Berryman-Maciel M, Darvish S, et al. Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: a study protocol. Front Physiol. 2022;13:980783. doi:10.3389/fphys.2022.980783 (NCT04851288)
Williamson J, Hughes CM, Cobley JN, Davison GW. The mitochondria-targeted antioxidant MitoQ, attenuates exercise-induced mitochondrial DNA damage. Redox Biol. 2020;36:101673. doi:10.1016/j.redox.2020.101673
Broome SC, Braakhuis AJ, Mitchell CJ, Merry TL. Mitochondria-targeted antioxidant supplementation improves 8 km time trial performance in middle-aged trained male cyclists. J Int Soc Sports Nutr. 2021;18(1):58. doi:10.1186/s12970-021-00454-0
Genova Diagnostics. Oxidative Stress 2.0, Urine: product information and collection instructions. Accessed November 2026.
Experience Life. A new age of at-home mitochondrial testing. Accessed November 2026.
Aminizadeh S, Lee J, Zarezadehmehrizi A, et al. MitoQ supplementation during vigorous training improves reactive oxygen species, glutathione peroxidase, and miRNAs regulating vascular inflammation in cyclists. Braz Arch Biol Technol. 2023;66. doi:10.1590/1678-4324-2023220914
Lin Y, Ji K, Ma X, et al. Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: a meta-analysis. Ann Clin Transl Neurol. 2020;7(7):1204-1213. doi:10.1002/acn3.51104
Precision Point Diagnostics. Advanced Oxidative Stress profile. Accessed November 2026.
Murray KO, Ludwig KR, Darvish S, et al. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. Am J Physiol Heart Circ Physiol. 2023;325(1):H187-H194. doi:10.1152/ajpheart.00270.2023
Masoumi-Ardakani Y, Najafipour H, Nasri HR, et al. Moderate endurance training and MitoQ improve cardiovascular function, oxidative stress, and inflammation in hypertensive individuals: the role of miR-21 and miR-222. A randomized, double-blind, clinical trial. Cell J. 2022;24(10):577-585. doi:10.22074/cellj.2022.8089
Park SY, Pekas EJ, Headid RJ, et al. Acute mitochondrial antioxidant intake improves endothelial function, antioxidant enzyme activity, and exercise tolerance in patients with peripheral artery disease. Am J Physiol Heart Circ Physiol. 2020;319(2):H456-H467. doi:10.1152/ajpheart.00235.2020
West AP, Shadel GS. Mitochondrial DNA in innate immune responses and inflammatory pathology. Nat Rev Immunol. 2017;17(6):363-375. doi:10.1038/nri.2017.21
Kirkman DL, Stock JM, Shenouda N, et al. Effects of a mitochondrial targeted ubiquinol (MitoQ) on vascular function and exercise capacity in chronic kidney disease: a randomized controlled pilot study. Am J Physiol Renal Physiol. 2023;325(4):F448-F456. doi:10.1152/ajprenal.00067.2023
Maruhashi T, Soga J, Fujimura N, et al. Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study. Heart. 2013;99(24):1837-1842. doi:10.1136/heartjnl-2013-304739
Genova Diagnostics. Measuring oxidative stress. August 2026.

